$1.440
-0.020 (-1.37%)At close
ACXP News
ACXP Events
Acurx Pharmaceuticals Presents Gut Microbiome Study in New York
Acurx Pharmaceuticals announced a poster presentation presented by Kevin Garey, University of Houston College of Pharmacy, Principal Investigator for microbiology at the 18th Biennial Congress of the Anaerobe Society of the Americas in New York City July 8 to 10. Studies were performed at the University of Houston to determine whether beneficial gut microbes are present in patients with multiple recurrences of Clostridioides difficile infection, or rCDI. The objectives of this study were to determine whether beneficial microbes identified in the IBZ Phase 2 studies in patients with initial and 1st recurrent CDI are still present in patients with multiple recurrent CDI and to assess killing effects of IBZ vs. comparators in planktonic and biofilm mono- and duo-culture studies; specifically, measuring killing of VRE by VAN, FDX, and IBZ in planktonic and biofilm cultures. Data demonstrated beneficial bacterial taxa persist in fecal samples from patients with rCDI despite multiple prior CDI treatments with the antibiotic standards of care, vancomycin and/or fidaxomicin. Following acute treatment with ibezapolstat, these beneficial microorganisms will have the opportunity to repopulate the microbiome in a beneficial way that may prevent recurrence. IBZ and FDX were superior in biofilm experimental models with IBZ significantly more effective at killing C. difficile than VAN and FDX.
Quarter Ends with Cash Totaling $9.3M
Ended the quarter with cash totaling $9.3M vs. $7.6M as of December 31, 2025.
Acurx Files to Sell 1.3M Shares of Common Stock
Acurx files to sell 1.3M shares of common stock for holders
Acurx Files to Sell 1.65M Shares of Common Stock
Acurx files to sell 1.65M shares of common stock for holders
Acurx Issues 825,085 Shares at $3.03 Each
Acurx announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 825,085 shares of its common stock at a purchase price of $3.03 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the company will issue unregistered short-term warrants to purchase up to 1,650,170 shares of common stock. The short-term warrants will have an exercise price of $2.78 per share, will be immediately exercisable upon issuance and will expire twenty-four months following the effective date of the registration statement registering the resale of the shares of common stock underlying the short-term warrants. The closing of the offering is expected to occur on or about April 16, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.